Business
Nuvaxovid (Novavax) Market Research Report 2026: Epidemiology, Pipeline Analysis, Trends, Strategies, and Forecasts, 2020-2025, 2025-2030F, 2035F
The Nuvaxovid market offers opportunities in booster immunizations, variant-adapted vaccines, and increased global vaccine coverage. Trends include protein-based platforms, adjuvant-enhanced vaccines, and cold-chain distribution. Challenges like tariffs drive domestic manufacturing, while demand rises due to infectious disease prevalence.Dublin, March 13, 2026 (GLOBE NEWSWIRE) -- The "Nuvaxovid Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts" has been added to Re
About this update from Novavax, Inc.
[{"type":"image","alt":"Company Logo","displaySize":"","headline":null,"caption":"Company Logo","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":36,"url":"https://media.zenfs.com/en/globenewswire.com/6a90a26a88cc04ec0d3fe15e0ab1be65"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/g_3H8YP5.WdAX5cBtX03VA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTUwO2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/6a90a26a88cc04ec0d3fe15e0ab1be65","width":300,"height":36}},"lazy":false},{"type":"text","content":"The Nuvaxovid market offers opportunities in booster immunizations, variant-adapted vaccines, and increased global vaccine coverage. Trends include protein-based platforms, adjuvant-enhanced vaccines, and cold-chain distribution. Challenges like tariffs drive domestic manufacturing, while demand rises due to infectious disease prevalence.","length":340,"tagName":"p"},{"type":"text","content":"Dublin, March 13, 2026 (GLOBE NEWSWIRE) -- The "Nuvaxovid Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts" has been added to ResearchAndMarkets.com's offering.","length":211,"tagName":"p"},{"type":"text","content":"The Nuvaxovid market research report offers a comprehensive view, providing industry statistics, global market size, regional shares, competitors, market trends, opportunities, and a deep analysis of current and future scenarios. Nuvaxovid, a protein-based vaccine, contains a recombinant spike protein with a Matrix-M adjuvant to enhance immune response, authorized for COVID-19 prevention in individuals 12 and older.","length":419,"tagName":"p"},{"type":"text","content":"During the historic period, the growth of the Nuvaxovid market was driven by global COVID-19 pandemic response initiatives, emergency authorizations for vaccines, large-scale immunization programs, increased public health funding, and rapid vaccine manufacturing scaling. Looking ahead, growth factors include sustained demand for booster shots, emphasis on variant-adapted vaccines, broader global vaccination coverage, diversification in vaccine technologies, and enhanced pandemic preparedness. Key trends involve protein-based vaccine platform adoption, adjuvant-enhanced immunogenicity focus, optimized cold-chain vaccine distribution, non-mRNA COVID-19 vaccine demand, and vigilant vaccine safety and efficacy mon...